Theravance Biopharma (TBPH) Set to Announce Quarterly Earnings on Tuesday

Theravance Biopharma (NASDAQ:TBPH) is set to issue its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Theravance Biopharma Stock Performance

Shares of Theravance Biopharma stock opened at $8.94 on Friday. The business’s 50 day moving average price is $8.29 and its 200 day moving average price is $8.69. The company has a market cap of $437.36 million, a price-to-earnings ratio of -9.72 and a beta of 0.25. Theravance Biopharma has a one year low of $7.44 and a one year high of $11.71.

Wall Street Analyst Weigh In

Several research firms have recently commented on TBPH. Leerink Partnrs lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. TD Cowen decreased their target price on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a report on Tuesday, August 6th. Leerink Partners lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $15.00 to $10.00 in a report on Tuesday, August 6th. StockNews.com lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a research report on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $13.75.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.